In vivo imaging of ER density to guide and improve tailored therapy for acquired anti-hormonal resistant breast cancer

In vivo imaging of ER density to guide and improve tailored therapy for acquired anti-hormonal resistant breast cancer - In vivo imaging of the ER receptor

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38021

Enrollment

Registered

2009-03-10

Start date

2010-02-01

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer metastasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Acquired antihormonal resistant advanced breast cancer showing progression after two or more lines of antihormonal treatment. 2. Treatment with estradiol. 3. Age >= 18 years 4. ECOG performance status 0-2 5. Signed written informed consent 6. Able to comply with the protocol

Exclusion criteria

Exclusion criteria: 1. Life-expectancy

Design outcomes

Primary

Measure	Time frame
Clinical/biochemical/radiological response on Estradiol versus ER expression on FES-PET signal preferable with an ER expressions density measured on recent taken tumor tissue	—

Secondary

Measure	Time frame
Physical burden of FES-PET	—

Countries

Netherlands

Outcome results